Iranian Journal of Nuclear Medicine

Iranian Journal of Nuclear Medicine

Preparation and preclinical evaluation of a Gd(ΙΙΙ)-RGD peptide for MR molecular imaging in non-small cell lung carcinoma (NSCLC)

Document Type : Original Article

Authors
Nazanin Pirooznia 1
khosrou Abdi 1, 2
Davood Beiki 3
Farshad Emami 4
Habibeh Vosoughi 5
1 Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2 Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
3 Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Nuclear Medicine and Molecular Imaging Department, Imam Reza International University, Razavi Hospital, Mashhad, Iran
5 Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
10.22034/irjnm.2023.129051.1538
Abstract
Introduction: Excessive expression of the αvβ3 integrin receptors is seen in rapidly multiplying endothelial cells, including cancerous growth of various tumors. αvβ3 integrin receptors’ specific targeting by peptides containing the RGD motif makes these short sequences a suitable nominee for diagnostic imaging and lung cancer follow-up. A high-affinity RGD-containing peptide is designed. The di-RGD peptide has a greater affinity along with tumor-selective targeting properties. Peptide labeling with gadolinium for magnetic resonance imaging was accomplished, permitting efficient cancer molecular imaging accompanied by high spatial resolution. This peptide will have better sensitivity for the early identification of tumors and is appropriate for follow-up routines.
Methods: DOTA-E(cRGDfK)2 was labeled with Gd(ΙΙΙ) effectively. The cytotoxicity to cells was measured. The biodistribution was evaluated in a mouse model for lung cancer. The very early diagnostic capacity of the Gd-RGD peptide was studied using MR molecular imaging.
Results: MR imaging shows high binding specificity of Gd(ΙΙΙ)-DOTA-E(cRGDfK)2 to A549 lung tumor in mice. Gd-DOTA-E(cRGDfK)2 did not show cytotoxicity at high concentrations and on different cell lines. Biodistribution studies confirm tumor uptake up to 24h after the injection. The peptide-based contrast agent leaded to an improved tumor contrast enhancement at a dose of 0.1 mmol Gd/kg. The tumor uptake peaks were after 30 min of injection. A clear picture of the tumor was seen in all images.
Conclusion: Gd(ΙΙΙ)-DOTA-E(cRGDfK)2 can be used as a peptidic MR imaging contrast agent enabling initial detection of different cancers overexpressing the αvβ3 integrin receptors and can be a prospective candidate in clinical studies of non-small cell lung carcinoma.
Keywords
RGD peptide
Gadolinium
MR imaging
Non-small cell lung carcinoma
Subjects
  1. American Cancer Society. Global Cancer Facts & Figures. Atlanta, GA, USA: American Cancer Society; available from: http:// www.cancer.org/.
  2. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018 Jun;7(3):220-233.
  3. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Translational lung cancer research. 2016 Jun;5(3):288.
  4. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Current pharmaceutical design. 2006 Aug 1;12(22):2723-47.
  5. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics. 2011;1:58.
  6. Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012 Nov 5;9(11):2961-73.
  7. Höltke C, Faust A. Molecular imaging of integrins in oncology. Rep Med Imaging. 2017 Jan 31;10:17-30.
  8. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci. 2006 Oct 1;119(Pt 19):3901-3. 
  9. Liu S, Hsieh WY, Kim YS, Mohammed SI. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug Chem. 2005 Nov-Dec;16(6):1580-8. 
  10. Liu S, He Z, Hsieh WY, Kim YS, Jiang Y. Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. Bioconjug Chem. 2006 Nov-Dec;17(6):1499-507.
  11. Liu S, Hsieh WY, Jiang Y, Kim YS, Sreerama SG, Chen X, Jia B, Wang F. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem. 2007 Mar-Apr;18(2):438-46. 
  12. Liu S, Kim YS, Hsieh WY, Gupta Sreerama S. Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. Nucl Med Biol. 2008 Jan;35(1):111-21. 
  13. Dijkgraaf I, Yim CB, Franssen GM, Schuit RC, Luurtsema G, Liu S, Oyen WJ, Boerman OC. PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):128-37.
  14. Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1296-307. 
  15. Liu Z, Niu G, Shi J, Liu S, Wang F, Liu S, Chen X. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):947-57.
  16. Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem. 2009 Jan 22;52(2):425-32. 
  17. Steiger K, Quigley NG, Groll T, Richter F, Zierke MA, Beer AJ, Weichert W, Schwaiger M, Kossatz S, Notni J. There is a world beyond αvβ3-integrin: multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography. EJNMMI Res. 2021 Oct 12;11(1):106. 
  18. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010 Jul;65(7):500-16.
  19. Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK. MRI contrast agents: Classification and application (Review). Int J Mol Med. 2016 Nov;38(5):1319-26. 
  20. Blumfield E, Swenson DW, Iyer RS, Stanescu AL. Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients. Pediatr Radiol. 2019 Apr;49(4):448-457. 
  21. Clough TJ, Jiang L, Wong KL, Long NJ. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents. Nat Commun. 2019 Mar 29;10(1):1420. 
  22. Valdés PA, Moses ZB, Kim A, Belden CJ, Wilson BC, Paulsen KD, Roberts DW, Harris BT. Gadolinium- and 5-aminolevulinic acid-induced protoporphyrin IX levels in human gliomas: an ex vivo quantitative study to correlate protoporphyrin IX levels and blood-brain barrier breakdown. J Neuropathol Exp Neurol. 2012 Sep;71(9):806-13. 
  23. Wu X, Yu G, Lindner D, Brady-Kalnay SM, Zhang Q, Lu ZR. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. Am J Nucl Med Mol Imaging. 2014 Jul 15;4(6):525-36. 
  24. Li Y, Han Z, Roelle S, DeSanto A, Sabatelle R, Schur R, Lu ZR. Synthesis and assessment of peptide Gd-DOTA conjugates targeting extradomain B fibronectin for magnetic resonance molecular imaging of prostate cancer. Mol Pharm. 2017 Nov 6;14(11):3906-3915.
  25. Pirooznia N, Abdi K, Beiki D, Emami F, Arab SS, Sabzevari O, Pakdin-Parizi Z, Geramifar P. Radiosynthesis, biological evaluation, and preclinical study of a 68Ga-labeled cyclic RGD peptide as an early diagnostic agent for overexpressed αvβ3 integrin receptors in Non-Small-Cell lung cancer. Contrast Media Mol Imaging. 2020 Mar 31;2020:8421657.
  26. Pirooznia N, Abdi K, Beiki D, Emami F, Arab SS, Sabzevari O, Soltani-Gooshkhaneh S. 177Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: biological evaluation and preclinical study. Bioorg Chem. 2020 Sep;102:104100.
  27. Li L, Chen X, Yu J, Yuan S. Preliminary clinical application of RGD-containing peptides as PET radiotracers for imaging tumors. Front Oncol. 2022 Mar 2;12:837952. 
  28. Jin J, Xu Z, Zhang Y, Gu YJ, Lam MH, Wong WT. Upconversion nanoparticles conjugated with Gd(3+) -DOTA and RGD for targeted dual-modality imaging of brain tumor xenografts. Adv Healthc Mater. 2013 Nov;2(11):1501-12.